Haleon plc (HLN)vsTeva Pharma Industries Ltd ADR (TEVA)
HLN
Haleon plc
$9.11
-2.04%
HEALTHCARE · Cap: $40.43B
TEVA
Teva Pharma Industries Ltd ADR
$35.73
-0.78%
HEALTHCARE · Cap: $41.93B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 57% more annual revenue ($17.35B vs $11.03B). HLN leads profitability with a 15.1% profit margin vs 9.0%. TEVA appears more attractively valued with a PEG of 1.50. HLN earns a higher WallStSmart Score of 63/100 (C+).
HLN
Buy63
out of 100
Grade: C+
TEVA
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-22.4%
Fair Value
$9.12
Current Price
$9.11
$0.01 premium
Margin of Safety
+46.3%
Fair Value
$63.92
Current Price
$35.73
$28.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 92.0% YoY
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Earnings expanding 72.2% YoY
Every $100 of equity generates 22 in profit
Areas to Watch
Expensive relative to growth rate
0.6% revenue growth
Moderate valuation
2.3% revenue growth
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on EPS Growth, Price/Book, Operating Margin. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, Return on Equity.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Bear Case : TEVA
The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow.
Key Dynamics to Monitor
TEVA carries more volatility with a beta of 0.86 — expect wider price swings.
TEVA is growing revenue faster at 2.3% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HLN scores higher overall (63/100 vs 62/100), backed by strong 15.1% margins. TEVA offers better value entry with a 46.3% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a prominent global player in the consumer health sector, dedicated to providing innovative health solutions through its diverse portfolio, which includes renowned brands like Sensodyne, Panadol, and Voltaren. Established as a spin-off from GlaxoSmithKline, the company leverages its strong brand equity to cater to critical health segments such as oral care, pain relief, and dietary supplements. Committed to sustainability and consumer-centric innovation, Haleon is strategically positioned to enhance health outcomes worldwide while pursuing growth and generating value for its shareholders through targeted investments and continuous product development.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?